ReviewHormone molecular biology and clinical investigation2015
Molecular cues on obesity signals, tumor markers and endometrial cancer.
Review in Hormone molecular biology and clinical investigation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 43 citations in OpenAlex.
- Article
- New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions.Cancer metastasis reviews · 2023Review
- Decreased Gene Expression of Antiangiogenic Factors in Endometrial Cancer: qPCR Analysis and Machine Learning Modelling.Cancers · 2023Article
- Article
- Colchicine ofCell journal · 2022Article
- Targeting LIF/LIFR signaling in cancer.Genes & diseases · 2022Review
- Vibrational Biospectroscopy: An Alternative Approach to Endometrial Cancer Diagnosis and Screening.International journal of molecular sciences · 2022Review
- Prospective Cohort Study of Pre- and Postdiagnosis Obesity and Endometrial Cancer Survival.Journal of the National Cancer Institute · 2022Article
- Models including preoperative plasma levels of angiogenic factors, leptin and IL-8 as potential biomarkers of endometrial cancer.Frontiers in oncology · 2022Article
- Review
- LIF/LIFR oncogenic signaling is a novel therapeutic target in endometrial cancer.Cell death discovery · 2021Article
- Incidence of Atrial Fibrillation in Postmenopausal Women with Endometrial Cancer.Journal of clinical medicine · 2021Article
- Identification of Predictive Biomarkers for Lymph Node Involvement in Obese Women With Endometrial Cancer.Frontiers in oncology · 2021Article
- Clinical value of selected markers of angiogenesis, inflammation, insulin resistance and obesity in type 1 endometrial cancer.BMC cancer · 2020Article
- The Suitability of FGF21 and FGF23 as New Biomarkers in Endometrial Cancer Patients.Diagnostics (Basel, Switzerland) · 2020Article
- Evaluation of the Impact of Cisplatin on Variances in the Expression Pattern of Leptin-Related Genes in Endometrial Cancer Cells.International journal of molecular sciences · 2020Article
- Gene expression changes and promoter methylation with the combined effects of estradiol and leptin in uterine tissue of the ovariectomized mice model of menopause.Molecular biology reports · 2020Article
- Leptin-induced Notch and IL-1 signaling crosstalk in endometrial adenocarcinoma is associated with invasiveness and chemoresistance.World journal of clinical oncology · 2019Article
- The influence of leptin on the process of carcinogenesis.Contemporary oncology (Poznan, Poland) · 2019Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Tumor markers are important tools for early diagnosis, prognosis, therapy response and endometrial cancer monitoring. A large number of molecular and pathologic markers have been described in types I and II endometrial cancers, which has served to define the main oncogenic, epidemiological, genetic, clinical and histopathological features. Ongoing attempts to stratify biological markers of endometrial cancer are presented. However, data on changes in tumor marker profiles in obesity-related endometrial cancer are scarce. Obesity is a pandemic in Western countries that has an important impact on endometrial cancers, albeit through not very well-defined mechanisms. Although endometrial cancer is more common in Caucasian women, higher mortality is found in African Americans who also show higher incidence of obesity. Here, we describe how obesity signals (estrogen, leptin, leptin induced-molecules, Notch; cytokines and growth factors) could affect endometrial cancer. Leptin signaling and its crosstalk may be associated to the more aggressive and poor prognosis type II endometrial cancer, which affects more postmenopausal and African-American women. In this regard, studies on expression of novel molecular markers (Notch, interleukin-1 and leptin crosstalk outcome) may provide essential clues for detection, prevention, treatment and prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.